Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-02-08
2011-02-08
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S134100, C424S135100, C424S136100, C424S138100, C424S152100, C424S155100, C424S156100, C424S172100, C424S174100, C530S387100, C530S387300, C530S387700, C530S388100, C530S388800, C530S388850, C530S391300, C530S391700
Reexamination Certificate
active
07883702
ABSTRACT:
The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed. Thus, various applications using such antibody are provided.
REFERENCES:
patent: 5627039 (1997-05-01), Pereira-Smith et al.
patent: 2001-354564 (2001-12-01), None
patent: WO 2001/44807 (2001-06-01), None
Wadhwa, R. et al. Histol. Histopathol (2002) 17: 1173-1177.
Wadhwa, R. et al., “Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the Hsp70 family protein mot-2 and reactivation of p53 function.” Cancer Res., 2000, p. 6818-21, vol. 60, No. 24.
Wadhwa, R. et al., “Identification of a novel member of mouse hsp70 family. Its association with Cellular mortal phenotype,” J. Biol. Chem., 1993, p. 6615-21, vol. 268, No. 9. Kaul, Z. et al., “Mortalin imaging in normal and cancer cells with quantum dot immuno-conjugates,” Cell Res., 2003, p. 503-7, vol. 13, No. 6.
Kanrei Murata et al., “RNA Kogaku kara no Ganchiryo eno Chosen”, Igaku no Ayumi, Apr. 10, 2004, p. 119-120, vol. 209, No. 2.
Ui-Tei, K. et al., Guidelines for the selection of highly effective siRNA sequences for mammalian and Chick RNA interference. Nucleic Acids Res., Feb. 9, 2004, p. 936-48, vol. 32, No. 3.
Takano, S. et al., Elevated levels of mortalin expression in human brain tumors, Exp. Cell Res., 1997, p. 38-45, vol. 237, No. 1.
“Challenges of RNA Engineering for Cancer Therapy.” Journal of Clinical and Experimental Medicine (Igaku no Ayumi), Apr. 10, 2004, p. 119-121, vol. 209, No. 2.
Kaul Sunil
Taira Kazunari
Wadhwa Renu
Harris Alana M.
Holleran Anne L
National Institute of Advanced Industrial Science and Technology
Sughrue & Mion, PLLC
LandOfFree
Use of anti-mortalin 2 antibody and functional nucleic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-mortalin 2 antibody and functional nucleic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-mortalin 2 antibody and functional nucleic acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2636409